Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Kesimpta (Ofatumumab) Zwangerschapsregister

9 november 2026 bijgewerkt door: Novartis Pharmaceuticals

Post-autorisatie veiligheidsonderzoek voor beoordeling van zwangerschap en baby-uitkomsten bij patiënten behandeld met Kesimpta (Ofatumumab) met behulp van OTIS Observational Pregnancy Surveillance Program en DMSKW-registratie

The Kesimpta Pregnancy Registry is an observational, exposure cohort designed study to examine pregnancy and infant outcomes in women and infants who are exposed to Kesimpta (ofatumumab) during pregnancy to treat MS.

Studie Overzicht

Toestand

Werving

Interventie / Behandeling

Gedetailleerde beschrijving

The study is expected to enroll for approximately 7 years and follow the pregnant women and their infant(s) over a maximum of 21 months.

The study will be conducted as two sub-studies leveraging independent ongoing pregnancy registries:

  • The Organization of Teratology Information Specialists (OTIS) Research Group, University of California, San Diego, USA (referred to as "OTIS") will serve as data source for the Kesimpta-OTIS sub-study;
  • The German MS and pregnancy registry - Deutschsprachigen Multiple Sklerose und Kinderwunsch Register (DMSKW) at Katholisches Klinikum Bochum gGmbH, St Josef Hospital, Bochum, Germany (referred to as "DMSKW") will serve as data source for the Kesimpta- DMSKW sub-study.

Both registries will independently collect and assess data related to the pregnancy and infant outcomes of interest and provide aggregate data which will be further combined (metaanalyses) by Novartis (referred to as the Sponsor) or a designated contract research organization (CRO).

Studietype

Observationeel

Inschrijving (Geschat)

725

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • California
      • La Jolla, California, Verenigde Staten, 92093-0934
        • Werving
        • University of California San Diego OTIS
        • Contact:
          • Telefoonnummer: 877-311-8972
        • Hoofdonderzoeker:
          • Christina Chambers

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 100 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Participants from sub-studies, namely the Kesimpta-OTIS sub-study and Kesimpta-DMSKW sub-study, of identical design, conducted in parallel, enrolling pregnant women (MS and non-MS) residing in US or Canada and pregnant women (MS only) from Germany respectively.

Beschrijving

Inclusion Criteria:

Participants must meet all the criteria listed under the respective cohorts to enroll in that particular cohort of the registry:

Cohort 1: Kesimpta-Exposed Cohort

  1. Pregnant women
  2. Diagnosed with MS, with the indication validated by medical records when possible
  3. Administered Kesimpta for the treatment of MS at any time from 166 days prior to the first day of the LMP, or up to and including the end of pregnancy
  4. Agree to the conditions and requirements of the study including the interview schedule, release of medical records, the dysmorphology examination of live born infants (OTIS specific), and validated developmental performance questionnaire in live born children

Cohort 2: Disease-Matched Comparison Cohort (Comparison Group 1)

  1. Pregnant women
  2. Diagnosed with MS, with the indication validated by medical records when possible
  3. May or may not have taken another medication for MS in the current pregnancy
  4. Agree to the conditions and requirements of the study including the interview schedule, release of medical records, the dysmorphology examination of live born infants (OTIS specific), and validated developmental performance questionnaire in live born children

Cohort 3: Healthy Comparison Cohort (Comparison Group 2):Kesimpta-OTIS sub-study specific

  1. Pregnant women
  2. Agree to the conditions and requirements of the study including the interview schedule, release of medical records, the dysmorphology examination of live born infants, and validated developmental performance questionnaire in live born children

Exclusion Criteria:

Women meeting any of the following criteria will be excluded from the cohort study:

Cohort 1: Kesimpta-Exposed Cohort

  1. Women who have enrolled in the Kesimpta cohort study with a previous pregnancy

  2. Women who have used Kesimpta for an indication other than a currently approved indication

  3. Women with exposure to any of the following medications within 5 half-lives (or pharmacodynamic effect when relevant) prior to conception:

    • Other anti-CD20 monoclonal antibody: same class as Kesimpta
    • S1P modulators: same class as Mayzent
    • Cladribine (Mavenclad): Based on the US label, animal studies indicate that there is positive evidence of teratogenicity for Cladribine
    • Teriflunomide (Aubagio): The teratogenecity of teriflunomide is unknown and currently under investigation.
    • New medications (marketed after 2021) indicated for the treatment of MS will be evaluated for inclusion/exclusion criteria as the study progresses.
  4. Retrospective enrollment after the outcome of pregnancy is known (i.e. the pregnancy has ended prior to enrollment)

  5. Results of diagnostic test(s) that are positive for a major structural defect prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate a major structural defect.

Cohort 2: Disease-Matched Comparison Cohort (Comparison Group 1)

  1. Administered Kesimpta 166 days before the first day of LMP or anytime during pregnancy

  2. Women with exposure to any of the following medications within 5 half-lives (or pharmacodynamic effect when relevant) of conception:

    • Anti CD-20 monoclonal antibody
    • Cladribine (Mavenclad)
    • S1P modulators
    • Teriflunomide (Aubagio) New medications (marketed after 2021) indicated for the treatment of MS will be evaluated for inclusion/exclusion criteria as the study progresses.
  3. Women who have enrolled in the Kesimpta cohort or BAF312A2403 Mayzent cohort with a previous pregnancy

  4. Retrospective enrollment after the outcome of pregnancy is known (i.e. the pregnancy has ended prior to enrollment)

  5. Results of diagnostic test(s) that are positive for a major structural defect prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate a major structural defect.

Cohort 3: Healthy Comparison Cohort (Comparison Group 2): Only applicable to Kesimpta-OTIS sub-study

  1. Administered Kesimpta 166 days before or Mayzent 4 days after the first day of LMP or anytime during pregnancy
  2. Women who have a diagnosis of a MS
  3. Women who have a current diagnosis of any autoimmune disease
  4. Women who have first contact with the project after prenatal diagnosis of any major structural defect
  5. Women treated with Mayzent or Kesimpta for non-MS indication
  6. Retrospective enrollment after the outcome of pregnancy is known (i.e. the pregnancy has ended prior to enrollment)
  7. Results of diagnostic test(s) that are positive for a major structural defect prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate a major structural defect.
  8. Women exposed to a known human teratogenic drugs during pregnancy

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Disease-matched cohort (Comparison Group 1)

comparison group consisting of women diagnosed with MS who have not used Kesimpta during pregnancy (unexposed disease-matched comparison group).

Healthy cohort (only applicable in the Kesimpta-OTIS sub-study) (Comparison Group 2)

healthy women who are not diagnosed with MS or any other autoimmune disease, have not had exposure to a known human teratogen, and have not taken Kesimpta in pregnancy (healthy comparison group). Since the DMSKW register is an MS population specific register that does not collect data on non-MS population, this cohort is only applicable in the Kesimpta-OTIS sub-study.

Kesimpta-exposed cohort

women and infants who are exposed to Kesimpta during pregnancy to treat MS.

Prospective non-interventional study. There is no treatment allocation. Patients participating in from the two independent sub-studies, namely the Kesimpta-OTIS sub-study and Kesimpta-DMSKW sub-study, of identical design, conducted in parallel, enrolling pregnant women (MS and non-MS) residing in US or Canada and pregnant women (MS only) from Germany respectively are eligible for enrolling to this study.

Andere namen:
  • Ofatumumab

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of participants with major structural defects
Tijdsspanne: Up to 21 months

Number of participants with major structural defects will be collected

Up to 21 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of participants with spontaneous abortion/miscarriage
Tijdsspanne: Up to 21 months

Number of participants with spontaneous abortion/miscarriage will be collected

Up to 21 months
Number of stillbirth cases
Tijdsspanne: Up to 21 months

Number of stillbirth cases will be collected

Up to 21 months
Number of elective termination cases
Tijdsspanne: Up to 21 months

Number of elective termination cases will be collected

Up to 21 months
Number of preterm delivery cases
Tijdsspanne: Up to 21 months

Number of preterm delivery cases will be collected

Up to 21 months
Number of preeclampsia / eclampsia cases
Tijdsspanne: Up to 21 months

Number of preeclampsia / eclampsia cases will be collected

Up to 21 months
Number of cases with pattern of 3 or more minor structural defects
Tijdsspanne: Up to 21 months

Number of cases with pattern of 3 or more minor structural defects will be collected

Up to 21 months
Number of participants small for gestational age
Tijdsspanne: Up to 21 months

Number of participants small for gestational age will be collected

Up to 21 months
Number of participants with postnatal growth small for age at one year of age
Tijdsspanne: Up to 21 months

Number of participants with postnatal growth small for age at one year of age will be collected

Up to 21 months
Developmental performance at approximately one year of age: Michaelis developmental milestones questionnaires
Tijdsspanne: Up to 21 months

The Michaelis developmental milestones questionnaires will be used to assess the developmental performance in live born infants.

Up to 21 months
Developmental performance at approximately one year of age: Denver developmental screening test
Tijdsspanne: Up to 21 months

Denver developmental screening test will be used to assess the developmental performance in live born infants;

Up to 21 months
Number of serious or opportunistic infections in the first year of life.
Tijdsspanne: Up to 21 months

Number of serious or opportunistic infections in the first year of life will be collected

Up to 21 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

5 januari 2023

Primaire voltooiing (Geschat)

28 februari 2033

Studie voltooiing (Geschat)

28 februari 2033

Studieregistratiedata

Eerst ingediend

22 november 2022

Eerst ingediend dat voldeed aan de QC-criteria

22 november 2022

Eerst geplaatst (Werkelijk)

2 december 2022

Updates van studierecords

Laatste update geplaatst (Werkelijk)

10 november 2026

Laatste update ingediend die voldeed aan QC-criteria

9 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren